Judit Jimenez Sainz

Dr. Judit Jimenez Sainz

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLiana Goehring
Liana Goehring
SKSarah Keegan
Sarah Keegan
SLSudipta Lahiri
Sudipta Lahiri
WXWenxin Xia
Wenxin Xia
MKMichael Kong
Michael Kong
THTony T. Huang
Tony T. Huang
BRCA2 is a tumor suppressor protein responsible for safeguarding the cellular genome from replication stress and genotoxicity, but the specific mechanism(s) by which this is achieved to prevent early oncogenesis remains unclear. Here, we provide evidence that BRCA2 acts as a critical suppressor of head-on transcription-replication conflicts (HO-TRCs). Using Okazaki-fragment sequencing (Ok-seq) and computational analysis, we identified origins (dormant origins) that are activated near the transcription termination sites (TTS) of highly expressed, long genes in response to replication stress. Dormant origins are a source for HO-TRCs, and drug treatments that inhibit dormant origin firing led to a reduction in HO-TRCs, R-loop formation, and DNA damage. Using super-resolution microscopy, we showed that HO-TRC events track with elongating RNA polymerase II, but not with transcription initiation. Importantly, RNase H2 is recruited to sites of HO-TRCs in a BRCA2-dependent manner to help alleviate toxic R-loops associated with HO-TRCs. Collectively, our results provide a mechanistic basis for how BRCA2 shields against genomic instability by preventing HO-TRCs through both direct and indirect means occurring at predetermined genomic sites based on the pre-cancer transcriptome.

20 May 2021 in Genes
Verified
Journal Article
Open access
PDF file
JSJudit Jimenez Sainz
Judit Jimenez Sainz
RJRyan Jensen
Ryan Jensen
Pathological mutations in homology-directed repair (HDR) genes impact both future cancer risk and therapeutic options for patients. HDR is a high-fidelity DNA repair pathway for resolving DNA double-strand breaks throughout the genome. BRCA2 is an essential protein that mediates the loading of RAD51 onto resected DNA breaks, a key step in HDR. Germline mutations in BRCA2 are associated with an increased risk for breast, ovarian, prostate, and pancreatic cancer. Clinical findings of germline or somatic BRCA2 mutations in tumors suggest treatment with platinum agents or PARP inhibitors. However, when genetic analysis reveals a variant of uncertain significance (VUS) in the BRCA2 gene, precision medicine-based decisions become complex. VUS are genetic changes with unknown pathological impact. Current statistics indicate that between 10–20% of BRCA sequencing results are VUS, and of these, more than 50% are missense mutations. Functional assays to determine the pathological outcome of VUS are urgently needed to provide clinical guidance regarding cancer risk and treatment options. In this review, we provide a brief overview of BRCA2 functions in HDR, describe how BRCA2 VUS are currently assessed in the clinic, and how genetic and biochemical functional assays could be integrated into the clinical decision process. We suggest a multi-step workflow composed of robust and accurate functional assays to correctly evaluate the potential pathogenic or benign nature of BRCA2 VUS. Success in this precision medicine endeavor will offer actionable information to patients and their physicians.

13 September 2022 in eLife
Verified
Journal Article
Open access
JSJudit Jimenez Sainz
Judit Jimenez Sainz
JMJoshua Mathew
Joshua Mathew
GMGemma Moore
Gemma Moore
SLSudipta Lahiri
Sudipta Lahiri
JGJennifer Garbarino
Jennifer Garbarino
RJRyan Jensen
Ryan Jensen
Pathogenic mutations in the BRCA2 tumor suppressor gene predispose to breast, ovarian, pancreatic, prostate, and other cancers. BRCA2 maintains genome stability through homology-directed repair (HDR) of DNA double-strand breaks (DSBs) and replication fork protection. Nonsense or frameshift mutations leading to truncation of the BRCA2 protein are typically considered pathogenic; however, missense mutations resulting in single amino acid substitutions can be challenging to functionally interpret. The majority of missense mutations in BRCA2 have been classified as Variants of Uncertain Significance (VUS) with unknown functional consequences. In this study, we identified three BRCA2 VUS located within the BRC repeat region to determine their impact on canonical HDR and fork protection functions. We provide evidence that S1221P and T1980I, which map to conserved residues in the BRC2 and BRC7 repeats, compromise the cellular response to chemotherapeutics and ionizing radiation, and display deficits in fork protection. We further demonstrate biochemically that S1221P and T1980I disrupt RAD51 binding and diminish the ability of BRCA2 to stabilize RAD51-ssDNA complexes. The third variant, T1346I, located within the spacer region between BRC2 and BRC3 repeats, is fully functional. We conclude that T1346I is a benign allele, whereas S1221P and T1980I are hypomorphic disrupting the ability of BRCA2 to fully engage and stabilize RAD51 nucleoprotein filaments. Our results underscore the importance of correctly classifying BRCA2 VUS as pathogenic variants can impact both future cancer risk and guide therapy selection during cancer treatment.

25 September 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJudit Jimenez Sainz
Judit Jimenez Sainz
JMJoshua Mathew
Joshua Mathew
GMGemma Moore
Gemma Moore
SLSudipta Lahiri
Sudipta Lahiri
JGJennifer Garbarino
Jennifer Garbarino
RJRyan B. Jensen
Ryan B. Jensen
BRCA2 is a tumor suppressor gene that maintains genome stability by mediating the high fidelity repair of DNA double-strand breaks (DSBs) through homology-directed repair (HDR). Pathogenic mutations in BRCA2 predispose to breast, ovarian, pancreatic, prostate, and other cancers. Mutations in BRCA2 leading to severe protein truncation predict pathogenicity, however, missense mutations with unknown functional consequences, designated Variants of Uncertain Significance (VUS), comprise 60% of BRCA2 sequence changes deposited in clinical databases. Classifying BRCA2 VUS correctly is critical for relaying clinically actionable information to patients concerning future cancer risk or current treatment options. In this study, we identified and biochemically characterized three BRCA2 VUS located in BRC repeats to determine the impact on canonical HDR functions. Two of the germline variants, S1221P and T1980I, map to conserved residues in BRC2 and BRC7, disrupt RAD51 binding, and are diminished in their ability to stabilize RAD51-ssDNA complexes. We provide supporting cellular evidence that S1221P and T1980I are significantly compromised in their response to chemotherapeutics and ionizing radiation. The third variant, T1346I, lies within the spacer region between BRC2 and BRC3 but remains fully functional. We conclude that T1346I has a neutral impact on BRCA2 function, while S1221P and T1980I are hypomorphic alleles that disrupt the ability of BRCA2 to fully engage and stabilize RAD51 nucleoprotein filaments. Conclusions/Highlights - The BRCA2 missense variants, S1221P in BRC2 and T1980I in BRC7, are hypomorphic alleles which exhibit multiple defects in response to chemotherapeutics, DNA damage, and cellular stress. - The biochemical defects in S1221P and T1980I include disruption of RAD51 binding and failure to stimulate RAD51-ssDNA complex formation. - Identification of a tumor derived somatic BRCA2 missense mutation in the spacer region between BRC2 and BRC3, T1346I, is a benign variant. Potential Limitations Given that BRCA2 plays several roles in cellular function, it is possible that the VUS studied disrupt BRCA2 function in ways not measured by the assays described here. Therefore, further experimentation is necessary to validate the observed functionality of the variants studied and discern partial loss of function variants from fully neutral or pathogenic ones. Overexpression of the BRCA2 cDNA may underestimate the functional effect of some variants. However, it is feasible that cDNA-based overexpression of these variants can partially rescue HR and other BRCA2 functions. Caution is warranted when interpreting results from an assay focusing on a single specific biochemical activity to predict pathogenicity of BRCA2. This is extremely challenging for proteins with multiple biochemical and biological functions such as BRCA2. Up to date a small number of pathogenic or non-pathogenic variants have been evaluated and based on. Therefore, discriminating a true intermediate function variant from a neutral or fully pathogenic variant remains difficult and integration of multiple functional assays may be necessary as the presented in this study.